selected publications
- CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit. 2024 GET IT
- Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer research. 2022 Academic Article GET IT
-
Multipurposing CARs: Same engine, different vehicles.
Molecular therapy : the journal of the American Society of Gene Therapy.
2022
Review
GET IT
Times cited: 8 -
Medicine and surgery residents' perspectives on the impact of COVID-19 on graduate medical education.
Medical education online.
2020
Academic Article
GET IT
Times cited: 74 -
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Nature reviews. Clinical oncology.
2019
Review
GET IT
Times cited: 736 -
The genetics of splicing in neuroblastoma.
Cancer discovery.
2015
Academic Article
GET IT
Times cited: 13 -
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.
Cell reports.
2014
Academic Article
GET IT
Times cited: 21 -
Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer.
Epigenetics.
2013
Academic Article
GET IT
Times cited: 16 -
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics.
Genes & development.
2012
Academic Article
GET IT
Times cited: 66 -
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
Cancer cell.
2012
Academic Article
GET IT
Times cited: 165 -
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Science translational medicine.
2012
Academic Article
GET IT
Times cited: 69 -
Akt and autophagy cooperate to promote survival of drug-resistant glioma.
Science signaling.
2010
Academic Article
GET IT
Times cited: 256 -
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
Nature medicine.
2010
Academic Article
GET IT
Times cited: 171 -
Pleiotropic role for MYCN in medulloblastoma.
Genes & development.
2010
Academic Article
GET IT
Times cited: 147 - A translational end-run for a rare, genetically enigmatic tumor. Cancer biology & therapy. 2009 Academic Article GET IT
-
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.
Cancer research.
2009
Academic Article
GET IT
Times cited: 64 -
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Cancer research.
2007
Academic Article
GET IT
Times cited: 184 -
Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy.
Genome biology.
2007
Review
GET IT
Times cited: 51 -
Structure-based prediction of insertion-site preferences of transposons into chromosomes.
Nucleic acids research.
2006
Academic Article
GET IT
Times cited: 64 -
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
Cancer research.
2003
Academic Article
GET IT
Times cited: 99 -
Genetic determinants of malignancy in a mouse model for oligodendroglioma.
Cancer research.
2003
Academic Article
GET IT
Times cited: 149